SuperworthThermo Fisher Scientific Inc. TMO
Medical - Diagnostics & Research, Healthcare
$655.30
−1.02%
- Market cap
- $242.3B
- PE
- 35.6×
- 10y median 32.8×
- Forward PE
- Price to sales
- 5.3×
- EV/EBIT
- 34.2×
- Revenue, 12 months
- $46.3B
- +7% on a year ago
- Net margin
- 15.0%
- Free cash flow yield
- 3.0%
Thermo Fisher Scientific trades at 35.6× trailing earnings, pricier than 68% of the last ten years. Revenue was $46.3B over the last twelve months, up 7% on a year earlier with a 15% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $10.9B | $10.3B | $10.5B | $10.6B | $11.4B+5% | $10.4B+0% | $10.9B+3% | $11.1B+5% | $12.2B+7% | $11B+6% | $12B+11% | |
| Cost of revenue | $6.9B | $6.1B | $6.2B | $6.3B | $6.9B−0% | $6.1B−0% | $6.4B+4% | $6.5B+5% | $7.2B+4% | $6.5B+7% | $7.1B+9% |
| Gross profit | $4B | $4.2B | $4.3B | $4.3B | $4.5B+13% | $4.2B+1% | $4.4B+2% | $4.6B+6% | $5B+12% | $4.5B+5% | $4.9B+12% |
| R&D | $327M | $331M | $339M | $346M | $374M+14% | $342M+3% | $352M+4% | $346M+0% | $356M−5% | $336M−2% | $364M+3% |
| SG&A | $2.1B | $2.2B | $2.1B | $2.1B | $2.2B+3% | $2.1B−5% | $2.1B+1% | $2.2B+3% | $2.4B+7% | $2.2B+5% | $2.3B+9% |
| $1.9B | $1.7B | $1.8B | $1.8B | $2B+9% | $1.7B+3% | $1.8B+1% | $1.9B+6% | $2.3B+12% | $1.9B+9% | $2.1B+14% | |
| Interest expense | $444M | $363M | $421M | $424M | $384M−14% | $303M−17% | $404M−4% | $347M−18% | $365M−5% | $354M+17% | $401M−1% |
| Pre-tax income | $1.7B | $1.6B | $1.8B | $1.7B | $1.9B+12% | $1.6B+2% | $1.7B−3% | $1.8B+5% | $2.2B+11% | $1.7B+7% | $1.9B+13% |
| $133M | $281M | $128M | $99M | $150M+13% | $95M−66% | $92M−28% | $207M+109% | $153M+2% | $70M−26% | $167M+82% | |
| Net income | $1.6B | $1.3B | $1.5B | $1.6B | $1.8B+14% | $1.5B+13% | $1.6B+5% | $1.6B−1% | $2B+7% | $1.7B+10% | $1.7B+7% |
| $4.20 | $3.46 | $4.04 | $4.25 | $4.78+14% | $3.98+15% | $4.28+6% | $4.27+1% | $5.21+9% | $4.43+11% | $4.68+9% | |
| 388M | 384M | 383M | 384M | 383M−1% | 379M−1% | 378M−1% | 378M−2% | 377M−2% | 373M−2% | 371M−2% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Diagnostics & Research within ten times Thermo Fisher Scientific's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TMOThermo Fisher Scientific Inc. | $244.8B | 35.6× | 32.8× | 5.3× | +7% | 15.0% | |
| DHRDanaher Corporation | $153.6B | 38.8× | 36.4× | 6.1× | +5% | 15.9% | |
| AAgilent Technologies, Inc. | $47.7B | 33.3× | 32.4× | 6.5× | +9% | 19.5% | |
| WATWaters Corporation | $42.8B | 109× | 29.3× | 9.2× | +52% | 3.6% | |
| IQVIQVIA Holdings Inc. | $42.5B | 32.0× | 35.0× | 2.5× | +8% | 8.1% | |
| ILMNIllumina, Inc. | $40.4B | 49.9× | 50.6× | 9.0× | +5% | 18.4% | |
| IDXXIDEXX Laboratories, Inc. | $39.9B | 35.6× | 54.8× | 8.8× | +13% | 25.0% | |
| MTDMettler-Toledo International Inc. | $30.7B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| LHLabcorp Holdings Inc. | $25.3B | 25.8× | 21.9× | 1.8× | +6% | 7.0% | |
| DGXQuest Diagnostics Incorporated | $25.1B | 24.1× | 19.1× | 2.2× | +10% | 9.2% | |
| Peer median | $40.4B | 34.5× | 35.0× | 6.5× | +8% | 15.9% |
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .